Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas

Seminars in Oncology

Volumn 25, Issue 2 SUPPL.4, 1998, Pages 33-39

  Adde, M ^a   Shad, A ^a   Venzon, D ^a   Arndt, C ^a   Gootenberg, J ^a   Neely, J ^a   Nieder, M ^a   Owen, W ^a   Seibel, N ^a   Wilson, W ^a   Horak, I D ^a   Magrath, I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; VINCRISTINE;

EID: 0031897786     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)